PURCHASE, N.Y., March 10, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical stage company developing product candidates that treat neurodegenerative disorders, (the “Company” or “Cognition”), announced that President and CEO Lisa Ricciardi will present live at the Life Sciences Virtual Investor Conference on March 13, 2025 at 9:30 a.m. ET. In her presentation, Ms. Ricciardi will review plans for 2025 to support the advancement of zervimesine (CT ...

Collaborators at the University of Southampton, UK and Cognition Scientists Show Rescue of Function in a Cell Model of Dry AMDPURCHASE, N.Y., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing neurodegenerative disease candidates, (the “Company” or “Cognition”) announced the publication of a manuscript reviewing recent work supporting the potential of zervimesine (CT1812), a small molecule drug candidate to treat dry age-related macular degener ...

Masked Analysis Shows Participants Receiving Oral Zervimesine for at Least 6 Months Experienced Slower Lesion Growth than Participants Receiving Placebo Following the Futility Analysis, Management Concluded the Phase 2 Study, Preserving Capital Full Analysis will be Provided in the Second Quarter of 2025 PURCHASE, N.Y., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, reported a positive outcome o ...

Core Insights - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing drugs for neurodegenerative disorders, particularly Alzheimer's disease and dementia with Lewy bodies [4] Group 1: Workshop and Presentation - Dr. Mary Hamby will co-host a precision medicine workshop at the Hanson Wade Neuroimmunology Drug Development Summit, focusing on participant screening methods for clinical trials [1] - The workshop will include an overview of findings from Cognition's Phase 2 'SHINE' study of zervimesine (CT1812), highlighting that participants with lower p-tau217 levels showed a 95% improvement on the ADAS-Cog 11 scale and a 108% improvement on the MMSE scale compared to placebo [2][3] Group 2: Diagnostic Potential - Plasma p-tau217 assays are suggested to be valuable not only as a diagnostic tool but also for identifying Alzheimer's patients who are most likely to benefit from therapies targeting beta amyloid [3] - The measurement of plasma p-tau217 can be conducted through a simple blood test, aiding in the personalization of treatment regimens for patients [3] Group 3: Company Overview - Cognition Therapeutics is currently investigating zervimesine in clinical programs for dementia with Lewy bodies and Alzheimer's disease, including the ongoing START study in early Alzheimer's disease [4] - Zervimesine is believed to interact with the sigma-2 receptor, offering a distinct mechanism for treating degenerative diseases [4]

Core Insights - Cognition Therapeutics, Inc. is advancing its clinical-stage drug development focused on neurodegenerative disorders, particularly Alzheimer's disease, with a significant emphasis on precision medicine [1][4] Group 1: Clinical Developments - Dr. Mary Hamby will co-host a workshop at the Hanson Wade Neuroimmunology Drug Development Summit to discuss participant screening methods for clinical trials [1] - The Phase 2 'SHINE' study of zervimesine (CT1812) showed that participants with lower p-tau217 levels had a 95% better score on the ADAS-Cog 11 scale and 108% better on the MMSE scale compared to those on placebo [2][3] Group 2: Diagnostic Potential - Plasma p-tau217 assays can serve as a diagnostic tool to identify Alzheimer's patients who are most likely to benefit from therapies targeting beta amyloid, enhancing personalized treatment approaches [3] Group 3: Company Overview - Cognition Therapeutics is focused on developing small molecule therapeutics for age-related degenerative disorders, with zervimesine being investigated in clinical programs for dementia with Lewy bodies and Alzheimer's disease [4]

Core Insights - Cognition Therapeutics, Inc. has developed a novel chemical process for manufacturing zervimesine (CT1812), enhancing its stability at room temperature and supporting future clinical studies and potential commercial manufacturing [1][2]. Group 1: Chemical Process and Patent Applications - The new manufacturing process utilizes innovative technologies such as high throughput screening and light-induced, continuous flow processing, which improves the efficiency and safety of zervimesine synthesis [2]. - Provisional patent applications have been filed for the new chemical process and a preferred polymorphic form of zervimesine [1]. Group 2: Zervimesine (CT1812) Overview - Zervimesine (CT1812) is an investigational oral medication aimed at treating central nervous system diseases, including Alzheimer's disease and dementia with Lewy bodies (DLB) [3]. - The drug targets the toxic effects of amyloid beta (Aβ) and ɑ-synuclein proteins, which are associated with neuron damage and cognitive decline in these diseases [3]. Group 3: Company Background - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system [4]. - The company is currently investigating zervimesine in clinical programs for DLB and Alzheimer's disease, including the ongoing START study [4].

Core Insights - Cognition Therapeutics, Inc. has developed a novel chemical process for manufacturing zervimesine (CT1812), enhancing its stability at room temperature and supporting future clinical studies and potential commercial manufacturing [1][2][3] Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related neurodegenerative disorders, particularly targeting Alzheimer's disease and dementia with Lewy bodies [4] - The company is currently investigating zervimesine (CT1812) in clinical programs, including the ongoing START study for early Alzheimer's disease [4] Product Information - Zervimesine (CT1812) is an investigational oral medication designed to treat central nervous system diseases, specifically targeting the toxic effects of amyloid beta (Aβ) and ɑ-synuclein proteins that damage neurons [3] - The new manufacturing process utilizes innovative technologies such as high throughput screening and light-induced continuous flow processing, which improves the efficiency and safety of zervimesine synthesis [2]

Core Insights - Cognition Therapeutics, Inc. announced topline results from the SHIMMER study of zervimesine (CT1812) in dementia with Lewy bodies, which will be presented at the International Lewy Body Dementia Conference [1][2] - The study demonstrated significant efficacy signals, with zervimesine-treated participants showing improvements across various symptoms compared to placebo [2][5] Study Overview - The SHIMMER study was a Phase 2 clinical trial involving 130 adults with mild-to-moderate dementia with Lewy bodies, randomized to receive either zervimesine or placebo for six months [8][9] - The study met its primary endpoint of safety and tolerability, with most treatment-related adverse events being mild or moderate [4][5] Efficacy Results - Zervimesine-treated participants scored an average of 86% better on the neuropsychiatric inventory (NPI) A-L compared to placebo [2][5] - Participants on zervimesine preserved 52% more ability in activities of daily living (ADCS-ADL) and showed a 91% reduction in cognitive fluctuations [3][5] - Improvements in motor function were also noted, with zervimesine-treated patients maintaining 62% better motor function than those on placebo [3][5] Implications for Patients - The positive outcomes suggest that zervimesine may allow patients with dementia with Lewy bodies to live at home longer with the support of caregivers, reducing the need for care facility placement [4][5] - The study highlights the potential for zervimesine to alleviate debilitating neuropsychiatric and motor symptoms associated with the disease [2][4] Company Background - Cognition Therapeutics is focused on developing innovative therapeutics for age-related degenerative disorders, with zervimesine being a lead candidate currently investigated in clinical programs for dementia with Lewy bodies and Alzheimer's disease [11]

Core Insights - Cognition Therapeutics, Inc. announced strong therapeutic responses for zervimesine (CT1812) in patients with mild-to-moderate dementia with Lewy bodies (DLB), showing significant improvements across various measures compared to placebo [1][2][3] Study Results - The Phase 2 SHIMMER study involved 130 adults with mild-to-moderate DLB, demonstrating that zervimesine-treated participants scored 86% better on behavioral outcomes, 52% better on activities of daily living, 91% better on cognitive fluctuations, and 62% better on motor symptoms compared to placebo [2][3][6] - Zervimesine treatment resulted in fewer hallucinations, delusions, anxiety, and agitation in patients, which are common debilitating symptoms of DLB [2][4] - The study met its primary endpoint of safety and tolerability, with most treatment-related adverse events being mild or moderate [4][6] Mechanism of Action - Zervimesine is designed to penetrate the blood-brain barrier and selectively bind to the sigma-2 receptor complex, which is involved in regulating cellular processes disrupted by neurodegenerative disease drivers [8] Company Overview - Cognition Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina, with zervimesine as its lead candidate [9]

Core Viewpoint - Cognition Therapeutics, Inc. is making significant progress in its clinical programs for neurodegenerative disorders, particularly Alzheimer's disease and dementia with Lewy bodies, and is preparing for key presentations and regulatory meetings in early 2025 [2][3]. Company Developments - CEO Lisa Ricciardi will participate in conferences during the JP Morgan Healthcare Conference week to discuss advancements made in 2024 [1][2]. - The company achieved positive topline results from its Phase 2 SHIMMER study in patients with dementia with Lewy bodies, with findings to be presented at the International Lewy Body Dementia Conference in January 2025 [2]. - Cognition Therapeutics is preparing for an end-of-Phase 2 meeting with the FDA to review results from its SHINE study in mild-to-moderate Alzheimer's disease, marking an important regulatory milestone [2]. - The company received clearance for the generic name of its candidate, CT1812, which will be known as zervimesine [2]. Upcoming Events - Cognition Therapeutics will present at the Longwood Healthcare Leaders Stanford Summit on January 11, 2025, and at the Sachs 8th Annual Neuroscience Innovation Forum on January 12, 2025 [3]. - The panel discussions will focus on accelerating drug development and innovations in Alzheimer's disease and other cognitive disorders [3]. Company Overview - Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for age-related degenerative disorders of the central nervous system and retina [3]. - The lead candidate, zervimesine, is being investigated in clinical programs for Alzheimer's disease, dementia with Lewy bodies, and dry age-related macular degeneration [3]. - The company believes that zervimesine and its pipeline of Ï-2 receptor modulators can effectively regulate impaired pathways in these diseases, offering a distinct approach compared to other treatments [3].